About Upstream Bio
Upstream Bio is a company based in Waltham (United States) founded in 2021 by Oren Becker. Upstream Bio has raised $400 million across 2 funding rounds from investors including Orbimed, HBM Healthcare Investments and Enavate Sciences. The company has 52 employees as of December 31, 2024. Upstream Bio offers products and services including Verekitug. Upstream Bio operates in a competitive market with competitors including Aclaris Therapeutics, Escient Pharmaceuticals, Nimbus Therapeutics, Alpine Immune Sciences and Septerna, among others.
- Headquarter Waltham, United States
- Employees 52 as on 31 Dec, 2024
- Founders Oren Becker
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Upstream Bio, Inc.
-
Annual Revenue
$2.37 M (USD)-0.42as on Dec 31, 2024
-
Net Profit
-$62.81 M (USD)-205.82as on Dec 31, 2024
-
EBITDA
-$77.67 M (USD)-93.93as on Dec 31, 2024
-
Total Equity Funding
$400 M (USD)
in 2 rounds
-
Latest Funding Round
$200 M (USD), Series B
Jun 08, 2023
-
Investors
Orbimed
& 12 more
-
Employee Count
52
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Upstream Bio
Upstream Bio is a publicly listed company on the NASDAQ with ticker symbol UPB in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Upstream Bio
Upstream Bio offers a comprehensive portfolio of products and services, including Verekitug.
Targets upstream drivers of inflammatory responses for disease treatment.
People of Upstream Bio
Unlock access to complete
Funding Insights of Upstream Bio
Upstream Bio has successfully raised a total of $400M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $200 million completed in June 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Upstream Bio
Upstream Bio has secured backing from 13 investors, including institutional and venture fund investors. Prominent investors backing the company include Orbimed, HBM Healthcare Investments and Enavate Sciences.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
VC & PE firm focused on healthcare sector
|
Locked | Locked | Locked | |
|
Investments are focused on pharmaceutical, biotechnology, and medical sectors.
|
Locked | Locked | Locked | |
|
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields.
|
Locked | Locked | Locked |
Investor details for Upstream Bio
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Upstream Bio
Investment portfolio details for Upstream Bio
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Upstream Bio
Detailed financials for Upstream Bio
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Upstream Bio Comparisons
Peer comparison for Upstream Bio
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Upstream Bio
Upstream Bio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Aclaris Therapeutics, Escient Pharmaceuticals, Nimbus Therapeutics, Alpine Immune Sciences and Septerna, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Novel dermatologic therapies are developed for skin conditions.
|
|
| Locked | Locked | Locked |
Small molecule therapeutics for inflammatory diseases are developed.
|
|
| Locked | Locked | Locked |
Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed.
|
|
| Locked | Locked | Locked |
Developer of immunotherapies to treat cancer and autoimmune disorders
|
|
| Locked | Locked | Locked |
GPCR drug discovery platform is developed for multiple diseases.
|
Detailed competitors of Upstream Bio
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Upstream Bio
Complete news archive for Upstream Bio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Upstream Bio
Upstream Bio was founded in 2021 and raised its 1st funding round 1 year after it was founded.
Upstream Bio is headquartered in Waltham, United States. It is registered at Waltham, Massachusetts, United States.
Upstream Bio is a funded company, having raised a total of $400M across 2 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Upstream Bio is 52.
Annual revenue of Upstream Bio is $2.37M as on Dec 31, 2024.
Upstream Bio was founded in 2021 and is headquartered in Waltham, United States. Therapeutics targeting allergic and inflammatory diseases are developed by the company within the biotechnology sector. Operations focus on monoclonal antibodies, with the lead candidate UPB-101 designed to inhibit the TSLP receptor on various immune cells involved in inflammatory conditions. Research and development activities are centered on advancing these treatments for multiple disease indications.
Upstream Bio's top competitors include Escient Pharmaceuticals, Nimbus Therapeutics and Alpine Immune Sciences.
Upstream Bio offers Verekitug.
Yes, Upstream Bio is publicly traded on NASDAQ under the ticker symbol UPB.
Upstream Bio has 13 investors. Key investors include Orbimed, HBM Healthcare Investments, Enavate Sciences, Altshuler Shaham, and Venrock Capital Partners.
The ticker symbol of Upstream Bio is UPB on NASDAQ.